Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells 5,760 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $21.43, for a total value of $123,436.80. Following the completion of the transaction, the insider now owns 24,592 shares in the company, valued at approximately $527,006.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Christine Ring also recently made the following trade(s):

• On Monday, July 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.81, for a total value of $119,865.60.
• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total value of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.00, for a total value of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total value of $27,147.96.

Nurix Therapeutics Stock Down 1.9 %

NASDAQ:NRIX traded down $0.41 during trading hours on Thursday, hitting $21.47. 540,187 shares of the company’s stock traded hands, compared to its average volume of 972,669. The firm has a market cap of $1.38 billion, a P/E ratio of -7.46 and a beta of 2.22. Nurix Therapeutics, Inc. has a 52 week low of $4.22 and a 52 week high of $24.38. The business’s fifty day simple moving average is $19.08 and its two-hundred day simple moving average is $14.71.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The firm had revenue of $12.09 million for the quarter, compared to the consensus estimate of $19.35 million. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.78 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA grew its position in Nurix Therapeutics by 248.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 142,146 shares of the company’s stock valued at $1,467,000 after acquiring an additional 101,320 shares during the last quarter. Trexquant Investment LP grew its holdings in shares of Nurix Therapeutics by 80.9% in the fourth quarter. Trexquant Investment LP now owns 159,318 shares of the company’s stock worth $1,644,000 after purchasing an additional 71,252 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Nurix Therapeutics by 176.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after purchasing an additional 440,112 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Nurix Therapeutics by 576.7% in the first quarter. Acadian Asset Management LLC now owns 160,293 shares of the company’s stock worth $2,355,000 after purchasing an additional 136,606 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after purchasing an additional 4,367 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NRIX. Truist Financial began coverage on Nurix Therapeutics in a research report on Wednesday. They set a “buy” rating and a $36.00 price target for the company. Needham & Company LLC cut their price target on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a report on Friday, July 12th. Royal Bank of Canada raised their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Friday, July 12th. Barclays raised their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Finally, HC Wainwright raised their price target on Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, June 18th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.